The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission

Annals of Oncology

Volumn 9, Issue SUPPL. 5, 1998, Pages

  Goldstone, A H ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

First remission; Hodgkin's disease; Stem cell transplant

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

AGE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE;

EID: 0032448066     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/9.suppl_5.S83     Document Type: Conference Paper

References (3)

1. Strauss DJ. High-risk Hodgkin's disease prognostic factors. Leuk Lymphoma 1995; 15 (Suppl 1): 41-2.
2. Proctor SJ et al. A numerical prognostic index for clinical use in identification of poor risk patients with Hodgkin's disease at diagnosis. Scottish and Newcastle Lymphoma Group (SNLG) Therapy Working Party. Eur J Cancer 1991; 27.5: 624-9.
3. Carella AM et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 1991; 8: 99-103.